Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2019 | MULTI-AG | $120,000,000 |
Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2017 | MULTI-AG | $33,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $541,000,000 |
Johnson & Johnson Vision Care, Inc. | Johnson & Johnson | price-fixing or anti-competitive practices | 2001 | MULTI-AG | $60,000,000 |
King Pharmaceuticals | Pfizer | False Claims Act and related | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $124,000,000 |
Kos Pharmaceuticals | AbbVie | kickbacks and bribery | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,454,432 |
Mallinckrodt LLC | Mallinckrodt | False Claims Act and related | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,500,000 |
Mallinckrodt plc | Mallinckrodt | price-fixing or anti-competitive practices | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $100,000,000 |
Medicis Pharmaceutical Corporation | Bausch Health | off-label or unapproved promotion of medical products | 2007 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,000,000 |
Merck | Merck | False Claims Act and related | 2008 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $290,000,000 |
Merck & Co. Inc. | Merck | consumer protection violation | 2009 | MULTI-AG | $5,400,000 |
Merck & Co. | Merck | consumer protection violation | 2008 | MULTI-AG | $58,000,000 |
Merck KGaA | Merck KGaA (EMD) | price-fixing or anti-competitive practices | 2009 | MULTI-AG | $2,275,454 |
Merck Sharp & Dohme Corp. | Merck | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $201,975,000 |
Mylan Inc. | Viatris | False Claims Act and related | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $465,000,000 |
Mylan Laboratories et al. | Viatris | price-fixing or anti-competitive practices | 2000 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $108,000,000 |
Mylan Pharmaceuticals, Inc. | Viatris | False Claims Act and related | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $118,000,000 |
Novartis Pharmaceuticals Corporation | Novartis | kickbacks and bribery | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $83,129,754 |
Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $88,258,694 |
Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $29,000,000 |
Novo Nordisk Inc. | Novo Holdings A/S | False Claims Act and related | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,320,963 |
Novo Nordisk Inc. | Novo Holdings A/S | off-label or unapproved promotion of medical products | 2011 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,574,209 |
Organon | Organon & Co. | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | $31,000,000 |
Organon USA Inc | Organon & Co. | price-fixing or anti-competitive practices | 2004 | MULTI-AG | $36,000,000 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,681,516 |
Ortho-McNeil Pharmaceutical, Inc. | Johnson & Johnson | False Claims Act and related | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,400,000 |
OSI Pharmaceuticals LLC | Astellas Pharma | False Claims Act and related | 2016 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,200,000 |
Otsuka American Pharmaceutical Inc. | Otsuka Pharmaceutical | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $1,700,000 |
Par Pharmaceutical Companies Inc. | Endo International | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $22,500,000 |
Par Pharmaceuticals, Inc. | Endo International | False Claims Act and related | 2011 | MULTI-AG | $154,000,000 |
Perrigo Company | Perrigo | price-fixing or anti-competitive practices | 2004 | MULTI-AG | $750,000 |
Pfizer | Pfizer | drug or medical equipment safety violation | 2003 | MULTI-AG | $6,000,000 |
Pfizer | Pfizer | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | $35,000,000 |
Pfizer Inc. | Pfizer | False Claims Act and related | 2002 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $21,084,700 |
Pfizer Inc. | Pfizer | False Claims Act and related | 2011 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,621,154 |
Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | $60,000,000 |
Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $42,900,000 |
Pfizer, Inc. | Pfizer | kickbacks and bribery | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $331,485,170 |
Purdue Frederick Company Inc. | Purdue Pharma | False Claims Act and related | 2007 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $160,000,000 |
Purdue Pharma | Purdue Pharma | off-label or unapproved promotion of medical products | 2007 | MULTI-AG | $19,500,000 |
Ranbaxy | Sun Pharmaceuticals | drug or medical equipment safety violation | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $266,729,715 |
Salix Pharmaceuticals Inc. | Bausch Health | kickbacks and bribery | 2016 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $7,470,000 |
Sanofi US Services, Inc. | Sanofi | kickbacks and bribery | 2013 | MULTI-AG | $617,000 |
SB Pharmco Puerto Rico Inc. | GlaxoSmithKline | drug or medical equipment safety violation | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $163,560,000 |
Schering-Plough Corporation | Merck | kickbacks and bribery | 2004 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $292,969,482 |
Schering-Plough Corporation | Merck | off-label or unapproved promotion of medical products | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $91,602,000 |
Schwarz Pharma Inc. | UCB | False Claims Act and related | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $9,756,164 |
Serono Inc. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $262,000,000 |
Shire Pharmaceuticals LLC | Takeda Pharmaceutical | False Claims Act and related | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,104,000 |
Shire Pharmaceuticals LLC | Takeda Pharmaceutical | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,786,034 |
SmithKline Beecham Corp. | GlaxoSmithKline | price-fixing or anti-competitive practices | 2005 | MULTI-AG | $10,000,000 |
Takeda Chemical | Takeda Pharmaceutical | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $17,551,650 |
TAP Pharmaceutical Products, Inc. | Takeda Pharmaceutical | False Claims Act and related | 2001 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $25,516,440 |
Teva Pharmaceuticals Inc. | Teva Pharmaceutical Industries | False Claims Act and related | 2010 | MULTI-AG | $169,000,000 |
UCB Inc. | UCB | off-label or unapproved promotion of medical products | 2011 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $9,893,322 |
UCB Pharma, Inc. | UCB | price-fixing or anti-competitive practices | 2009 | MULTI-AG | $2,275,454 |
Valeant Pharmaceuticals International, Inc. | Bausch Health | investor protection violation | 2017 | MULTI-AG | $145,000,000 |
Warner Chilcott Holdings | AbbVie | price-fixing or anti-competitive practices | 2007 | MULTI-AG | $5,500,000 |
Warner Chilcott PLC | AbbVie | False Claims Act and related | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $10,600,000 |
Warner-Lambert | Pfizer | off-label or unapproved promotion of medical products | 2004 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $190,000,000 |
Watson Pharmaceuticals | Teva Pharmaceutical Industries | False Claims Act and related | 2011 | MULTI-AG | $70,000,000 |
Wyeth Pharmaceuticals, Inc. | Pfizer | False Claims Act and related | 2016 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $371,351,180 |
Wyeth Pharmaceuticals, Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $257,400,000 |
Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2019 | MULTI-AG | $116,860,000 |
Avanir Pharmaceuticals | Otsuka Pharmaceutical | False Claims Act and related | 2019 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $7,000,000 |
Mallinckrodt | Mallinckrodt | Controlled Substances Act violation | 2020 | MULTI-AG | $1,600,000,000 |
Novartis Pharmaceuticals Corp. | Novartis | kickbacks and bribery | 2020 | MULTI-AG | $103,000,000 |
Pacira Pharmaceuticals, Inc. | Pacira BioSciences | kickbacks and bribery | 2020 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,500,000 |
Indivior plc | Indivior PLC | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $300,000,000 |
Bristol Myers Squibb Co. | Bristol-Myers Squibb | False Claims Act and related | 2021 | MULTI-AG | $75,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $5,000,000,000 |
Endo International plc | Endo International | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $450,000,000 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $2,370,000,000 |
Teva Pharmaceuticals | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $4,250,000,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $8,200,000 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $4,800,000 |
Indivior Inc. | Indivior PLC | price-fixing or anti-competitive practices | 2023 | MULTI-AG | $102,500,000 |
Hikma Pharmaceuticals | Hikma Pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $150,000,000 |
Dey LP | Viatris | False Claims Act and related | 2007 | MT-AG | $198,000 |
Janssen Ortho LLC and Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2014 | MT-AG | $5,900,000 |
Alere Inc. | Abbott Laboratories | kickbacks and bribery | 2017 | MS-AG | $2,000,000 |
Alpharma USPD, Inc., | Teva Pharmaceutical Industries | False Claims Act and related | 2011 | MS-AG | $2,010,667 |
Dey Labs | Viatris | False Claims Act and related | 2009 | MS-AG | $3,900,000 |
Eli Lilly | Eli Lilly | off-label or unapproved promotion of medical products | 2010 | MS-AG | $18,500,000 |
Par Pharmaceutical Co. | Endo International | False Claims Act and related | 2011 | MS-AG | $2,010,667 |
Purepac Pharmaceutical Co., n/k/a Actavis Elizabeth, LLC | Pfizer | False Claims Act and related | 2011 | MS-AG | $2,010,667 |
Sandoz, Inc. | Sandoz Group | False Claims Act and related | 2011 | MS-AG | $30,110,618 |
Watson, Inc. | Teva Pharmaceutical Industries | False Claims Act and related | 2018 | MS-AG | $33,408,547 |
Mallinckrodt/Covidien | Mallinckrodt | environmental violation | 2011 | MO-ENV | $6,000 |
Dey Inc. | Viatris | False Claims Act and related | 2006 | MO-AG | $2,932,000 |
Roxane, Inc. | Hikma Pharmaceuticals | False Claims Act and related | 2010 | MO-AG | $3,100,000 |
Schering-Plough | Merck | False Claims Act and related | 2008 | MO-AG | $31,000,000 |
Teva Pharmaceuticals USA | Teva Pharmaceutical Industries | environmental violation | 2013 | MO-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,402,793 |
Teva Pharmaceuticals USA Inc. | Teva Pharmaceutical Industries | environmental violation | 2003 | MO-AG | $70,000 |
Allergan Inc | AbbVie | wage and hour violation | 2019 | MI-LEO | $7,656 |
Otsuka American Pharmaceutical Inc | Otsuka Pharmaceutical | wage and hour violation | 2018 | MI-LEO | $12,500 |
Otsuka American Pharmaceutical Inc | Otsuka Pharmaceutical | wage and hour violation | 2018 | MI-LEO | $5,070 |
Allergan Usa Inc | AbbVie | wage and hour violation | 2017 | MI-LEO | $64,828 |
Allergan Plc | AbbVie | wage and hour violation | 2016 | MI-LEO | $73,999 |
Allergan Usa Inc | AbbVie | wage and hour violation | 2016 | MI-LEO | $73,999 |
Novartis Pharmaceuticals Corporation | Novartis | wage and hour violation | 2014 | MI-LEO | $13,000 |